The two companies announce a global collaboration to co-develop and co-commercialize bexobrutideg (NX-5948), an oral BTK degrader, across malignant hematology, immunology, and neurology.

The therapy targets CLL and other blood cancers with a market potential around $41 billion, and studies suggest bexobrutideg could offer greater tolerability and potential advantages over current treatments.

BTK inhibitors are a leading class in NHL/CLL with strong expected growth, underscoring the strategic significance of this partnership.

Nurix’s lead asset bexobrutideg has shown strong data, including an 83% objective response rate and a median progression-free survival of 22.1 months in heavily pretreated CLL patients.

The mechanism targets BTK for degradation to address both wild-type and mutant BTK, with potential applications in B-cell malignancies and immune-mediated diseases.

The clinical plan includes a Phase 3 program starting in the summer of 2026 for second-line chronic lymphocytic leukemia, with potential expansion into other B-cell malignancies, CSU, and multiple sclerosis.

In the United States, Nurix and Roche will co-develop and co-commercialize bexobrutideg; outside the U.S., Roche will lead commercialization and pay Nurix sales royalties in the low-to-high-teens range.

A conference call is planned for June 8, 2026, at 8:00 a.m. ET to discuss the collaboration, with Goldman Sachs acting as Nurix’s exclusive financial advisor.

The deal is subject to customary closing conditions, including Hart-Scott-Rodino antitrust review, with an expected close in the third quarter of 2026, and Roche will lead non-U.S. commercialization while Nurix maintains a strong U.S. development and commercialization role.

Bexobrutideg is an orally bioavailable, brain-penetrant BTK degrader that uses ubiquitin-proteasome–mediated degradation to eliminate BTK, aiming to overcome resistance seen with current BTK inhibitors.

Roche and Nurix executives emphasize the potential patient impact and strategic value of combining Roche’s portfolio with Nurix’s degrader technology.

Roche will pay Nurix $700 million upfront with potential total milestones up to $1.6 billion, and profits plus development costs are shared 60:40 in Roche’s favor, with profits afterward split evenly between the two companies.